Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 1372Terminated 500Recruiting 427Unknown 305Active not recruiting 234Withdrawn 132Not yet recruiting 87Suspended 15Enrolling by invitation 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 40Breast Neoplasms 40Prostatic Neoplasms 24Colorectal Neoplasms 24Uterine Cervical Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Anxiety Disorders 13Stomach Neoplasms 9Lymphoma, Follicular 9Lung Neoplasms 9Leukemia, Myeloid, Acute 9Carcinoma, Hepatocellular 8Brain Neoplasms 8Urinary Bladder Neoplasms 7Sarcoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Head and Neck Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Ovarian Neoplasms 6Epilepsy 6Depression 6Colonic Neoplasms 6Uterine Cervical Dysplasia 5Small Cell Lung Carcinoma 5Pain 5Glioma 5Dementia 5Cholangiocarcinoma 5Recurrence 4

Interventions

futibatinib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × Neoplasm Metastasis × Clear all
NCT06506955 2026-04-03

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation
15 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06508138 2026-03-06

J21112LINKED

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Enrolling by invitation
24 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡